A rapid response to pembrolizumab in a patient with metastatic melanoma.

Prognosis for patients with metastatic melanoma stays poor. Recent advances in the field of immuno-oncology increased treatment options for these patients and gave chances for obtaining partial and even complete response, prolonging survival in a subset of patients. Here, we describe a case of a 55-year-old man with multiple melanoma metastases into lungs who showed an extraordinary response to pembrolizumab used as a first-line treatment. The therapy was well tolerated, with no adverse reactions reported.